SIGA Technologies
| Company type | Public |
|---|---|
| Nasdaq: SIGA Russell 2000 Component | |
| Industry | Healthcare Biotechnology Health security |
| Founded | December 28, 1995 |
| Headquarters | , United States |
Key people | Diem Nguyen, Ph.D. (CEO) Dennis E. Hruby, Ph.D. (CSO) |
| Products | Pharmaceutical agents |
| Revenue | $133.7 million (2021) |
| $89.1 million (2021) | |
| $69.5 million (2021) | |
Number of employees | 39 (2022) |
| Website | siga |
| Footnotes / references | |
SIGA Technologies, Inc. is an American pharmaceutical company founded in 1995, based in New York City, which develops and sells pharmaceutical solutions for the antiviral treatment of smallpox, monkeypox, cowpox, and vaccinia complications.